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X-ray diffraction data sets were processed by using the HKL2000 program 1 . Prior to structure refinement, 5% randomly selected reflections were set aside for calculating R free as a monitor of model quality 2 . For Rv3378c, the MIR datasets of the mercury-containing derivatives were collected at a wavelength of 0.97622 Å. Using SOLVE and RESOLVE 3 , combinations of datasets from different Hgderivative crystals with the "native" dataset from the wild-type crystal improved the figure of merit (FOM) values from 0.52 to 0.66, the Z-scores from 10.85 to 14.1, and the number of auto-built amino acid residues to 181. Structures of the monoclinic crystals and the complex with BPH-629 were solved by molecular replacement using CNS 4 and a monomeric model from the tetragonal crystal. All subsequent structure refinements were carried out by using Coot 5 and CNS 4 . Data collection and refinement statistics are summarized in Table 1 and Table S1 in the Supporting Information. All Rv3378c crystals diffracted well to 2.1-2.8 A with R merge of 0.050-0.065 (Table 1) .
Crystallization, data collection and structure determination for Rv2361c (decaprenyl diphosphate synthase)
Rv2361c was expressed and purified as described previously 6 . For apo crystals, Rv2361c in 20 mM Tris (pH 7.2) containing 0.15 mM MgCl 2 and 3mM DTT was concentrated to 10mg/mL, and screened for crystallization using the JCSG Core Suites (QIAGEN, Valencia, CA) and the hanging drop method. Once initial crystallization conditions were found, they were optimized by varying the precipitant and protein concentrations. Optimal crystallization conditions were found to be 0.1 M HEPES (pH 7.5), 10% glycerol, 25% PEG 400, 7% PEG 3000, with 10 mg/mL Rv2361c. Apo Rv2361c crystals were then soaked in 1 mM BPH-640 in the same buffer for 5 hours to obtain inhibitor bound crystals. The X-ray diffraction data were indexed, integrated, and scaled by using the HKL2000 package 1 . Structures were determined by using molecular replacement with the program ccp4i 7 with the Rv2361c apo structure (PDB code 2VG4) as a template. Further model building and refinement employed Coot 5 and the ProDRG 8 server. All protein structure graphics were prepared by using the PyMOL program (http://www.pymol.org/).
Rv2361c Inhibition assay
Inhibition of Rv2361c by BPH-629 and BPH-640 was evaluated using [ 3 H]-IPP. Protein (0.1 µM) in 25 mM Tris buffer (pH 7.5) containing 0.01% Triton X100, 1mM MgCl 2 , 15 μM GPP and compound in a total volume of 50 μL was incubated at room temperature for 10 min. Then, 3.6 μL of IPP (containing 0.9 nmol cold IPP and 54.24 nCi [ 3 H]-IPP) was added, and the resulting mixture incubated at 37 °C for 20 min. The reaction was stopped with 500 µM NaCl saturated H 2 O. Prenyl alcohols were then extracted with 500 μL butanol, and a 300-μL aliquot was transferred to a scintillation vial for radioactivity counting. IC 50 values were obtained by using Origin software (OriginLab, Northampton, MA).
Tuberculosinol/(13R,S) iso-tuberculosinol synthase activity assay
A reaction mixture (2.5 mL) containing 50 mM Tris-HCl (pH 7.5), 1 mM MgCl 2 , 50 µg (44.4 µM) TPP, and 150 µg (1.76 µM) enzyme was incubated at 37°C for 14 hr. Reaction product analysis protocols were as described previously 9 .
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) measurements were carried out as described previously 10 . 
